FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317369439> ?p ?o ?g. }

• W2317369439 endingPage "371" @default.
• W2317369439 startingPage "361" @default.
• W2317369439 abstract "Pulmonary arterial hypertension is a chronic disease associated with poor long-term outcomes. Identifying predictors of long-term outcome in pulmonary arterial hypertension is important to assess disease severity and guide treatment. We investigate associations between efficacy parameters and long-term outcomes in patients with pulmonary arterial hypertension receiving riociguat in the PATENT-2 study. We also present safety and efficacy data from the final data cutoff of PATENT-2, where most patients had received at least 2 years of riociguat treatment.Eligible patients from the PATENT-1 study entered the PATENT-2 open-label extension, which will continue until all patients transition to the commercial drug. All patients received riociguat individually adjusted to a maximum dose of 2·5 mg three times a day. The primary endpoint was safety and tolerability, assessed with recording adverse events, serious adverse events, discontinuations, and deaths; exploratory assessments included 6-min walking distance (6MWD), WHO functional class, N-terminal prohormone of brain natriuretic peptide (NT-proBNP)concentrations, Borg dyspnoea score, health-related quality of life (EQ-5D score), survival, and clinical worsening-free survival. Association between efficacy parameters and long-term outcomes was assessed using Kaplan-Meier analyses and a Cox proportional-hazards regression model. PATENT-2 is registered at ClinicalTrials.gov, number NCT00863681.396 patients entered PATENT-2, of whom 197 patients were receiving riociguat monotherapy and 199 were receiving riociguat in combination with endothelin receptor antagonists or prostanoids, or both. A significant association was noted between 6MWD, NT-proBNP concentration, and WHO functional class and overall survival at baseline (p=0·0006, 0·0225, and 0·0191, respectively), and at follow-up (p=0·021, 0·0056, and 0·0048, respectively). Riociguat was well tolerated in PATENT-2. Serious adverse events were recorded in 238 (60%) of the total population, and 45 (11%) patients discontinued treatment because of an adverse event. Improvements in 6MWD, WHO functional class, and NT-proBNP concentrations were maintained after 2 years of treatment.These results support the long-term use of riociguat in patients with pulmonary arterial hypertension, and emphasise the prognostic value of 6MWD, WHO functional class, and NT-proBNP concentrations.Bayer Pharma AG." @default.
• W2317369439 created "2016-06-24" @default.
• W2317369439 creator A5010158442 @default.
• W2317369439 creator A5013077384 @default.
• W2317369439 creator A5031109105 @default.
• W2317369439 creator A5032089787 @default.
• W2317369439 creator A5042913937 @default.
• W2317369439 creator A5045687304 @default.
• W2317369439 creator A5045840018 @default.
• W2317369439 creator A5048931724 @default.
• W2317369439 creator A5080488240 @default.
• W2317369439 creator A5082059107 @default.
• W2317369439 creator A5083839456 @default.
• W2317369439 creator A5084935661 @default.
• W2317369439 creator A5086013885 @default.
• W2317369439 date "2016-05-01" @default.
• W2317369439 modified "2023-10-01" @default.
• W2317369439 title "Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial" @default.
• W2317369439 cites W1825951622 @default.
• W2317369439 cites W1866413456 @default.
• W2317369439 cites W1937664636 @default.
• W2317369439 cites W1978734517 @default.
• W2317369439 cites W1985704557 @default.
• W2317369439 cites W1986604107 @default.
• W2317369439 cites W2004950293 @default.
• W2317369439 cites W2076198557 @default.
• W2317369439 cites W2086130843 @default.
• W2317369439 cites W2095878489 @default.
• W2317369439 cites W2096352797 @default.
• W2317369439 cites W2102192501 @default.
• W2317369439 cites W2103763164 @default.
• W2317369439 cites W2107011819 @default.
• W2317369439 cites W2107337478 @default.
• W2317369439 cites W2108559440 @default.
• W2317369439 cites W2110637500 @default.
• W2317369439 cites W2114863766 @default.
• W2317369439 cites W2116602890 @default.
• W2317369439 cites W2143241675 @default.
• W2317369439 cites W2148067786 @default.
• W2317369439 cites W2150889420 @default.
• W2317369439 cites W2150989458 @default.
• W2317369439 cites W2151863430 @default.
• W2317369439 cites W2155231007 @default.
• W2317369439 cites W2158862125 @default.
• W2317369439 cites W2163585396 @default.
• W2317369439 cites W2167360168 @default.
• W2317369439 cites W2175995520 @default.
• W2317369439 cites W2278696749 @default.
• W2317369439 cites W2316662328 @default.
• W2317369439 cites W4230293260 @default.
• W2317369439 doi "https://doi.org/10.1016/s2213-2600(16)30019-4" @default.
• W2317369439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27067479" @default.
• W2317369439 hasPublicationYear "2016" @default.
• W2317369439 type Work @default.
• W2317369439 sameAs 2317369439 @default.
• W2317369439 citedByCount "86" @default.
• W2317369439 countsByYear W23173694392016 @default.
• W2317369439 countsByYear W23173694392017 @default.
• W2317369439 countsByYear W23173694392018 @default.
• W2317369439 countsByYear W23173694392019 @default.
• W2317369439 countsByYear W23173694392020 @default.
• W2317369439 countsByYear W23173694392021 @default.
• W2317369439 countsByYear W23173694392022 @default.
• W2317369439 countsByYear W23173694392023 @default.
• W2317369439 crossrefType "journal-article" @default.
• W2317369439 hasAuthorship W2317369439A5010158442 @default.
• W2317369439 hasAuthorship W2317369439A5013077384 @default.
• W2317369439 hasAuthorship W2317369439A5031109105 @default.
• W2317369439 hasAuthorship W2317369439A5032089787 @default.
• W2317369439 hasAuthorship W2317369439A5042913937 @default.
• W2317369439 hasAuthorship W2317369439A5045687304 @default.
• W2317369439 hasAuthorship W2317369439A5045840018 @default.
• W2317369439 hasAuthorship W2317369439A5048931724 @default.
• W2317369439 hasAuthorship W2317369439A5080488240 @default.
• W2317369439 hasAuthorship W2317369439A5082059107 @default.
• W2317369439 hasAuthorship W2317369439A5083839456 @default.
• W2317369439 hasAuthorship W2317369439A5084935661 @default.
• W2317369439 hasAuthorship W2317369439A5086013885 @default.
• W2317369439 hasConcept C126322002 @default.
• W2317369439 hasConcept C164705383 @default.
• W2317369439 hasConcept C168563851 @default.
• W2317369439 hasConcept C197934379 @default.
• W2317369439 hasConcept C203092338 @default.
• W2317369439 hasConcept C2776304953 @default.
• W2317369439 hasConcept C2777428986 @default.
• W2317369439 hasConcept C2778375690 @default.
• W2317369439 hasConcept C2780930700 @default.
• W2317369439 hasConcept C50382708 @default.
• W2317369439 hasConcept C71924100 @default.
• W2317369439 hasConceptScore W2317369439C126322002 @default.
• W2317369439 hasConceptScore W2317369439C164705383 @default.
• W2317369439 hasConceptScore W2317369439C168563851 @default.
• W2317369439 hasConceptScore W2317369439C197934379 @default.
• W2317369439 hasConceptScore W2317369439C203092338 @default.
• W2317369439 hasConceptScore W2317369439C2776304953 @default.
• W2317369439 hasConceptScore W2317369439C2777428986 @default.
• W2317369439 hasConceptScore W2317369439C2778375690 @default.
• W2317369439 hasConceptScore W2317369439C2780930700 @default.

• next